Switch theme
Sign up to access all valuation multiples
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
1901
47K+
LTM Revenue $47.1B
LTM EBITDA $17.3B
$815B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Eli Lilly has a last 12-month revenue of $47.1B and a last 12-month EBITDA of $17.3B.
In the most recent fiscal year, Eli Lilly achieved revenue of $45.0B and an EBITDA of $15.2B.
Eli Lilly expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Eli Lilly valuation multiples based on analyst estimates| FY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $28.5B | $34.1B | $45.0B | $47.1B | XXX |
| Gross Profit | $21.9B | $27.0B | $36.6B | XXX | XXX |
| Gross Margin | 77% | 79% | 81% | XXX | XXX |
| EBITDA | $8.7B | $8.6B | $15.2B | $17.3B | XXX |
| EBITDA Margin | 30% | 25% | 34% | 37% | XXX |
| Net Profit | $6.2B | $5.2B | $10.6B | XXX | XXX |
| Net Margin | 22% | 15% | 24% | XXX | XXX |
| Net Debt | $14.2B | $22.4B | $30.4B | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 21, 2025, Eli Lilly's stock price is $874.
Eli Lilly has current market cap of $785B, and EV of $815B.
See Eli Lilly trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $815B | $785B | XXX | XXX | XXX | XXX | $14.44 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 21, 2025, Eli Lilly has market cap of $785B and EV of $815B.
Eli Lilly's trades at 17.3x LTM EV/Revenue multiple, and 47.2x LTM EBITDA.
Analysts estimate Eli Lilly's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Eli Lilly and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $815B | XXX | XXX | XXX |
| EV/Revenue | 18.1x | XXX | XXX | XXX |
| EV/EBITDA | 53.5x | XXX | XXX | XXX |
| P/E | 74.1x | XXX | XXX | XXX |
| P/E/Growth | 1.3x | XXX | XXX | XXX |
| EV/FCF | 1967.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpEli Lilly's NTM/LTM revenue growth is 29%
Eli Lilly's revenue per employee for the last fiscal year averaged $1.0M, while opex per employee averaged $0.4M for the same period.
Over next 12 months, Eli Lilly's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Eli Lilly's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Eli Lilly and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 32% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 78% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 63% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.0M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 18% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 24% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 42% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Eli Lilly acquired XXX companies to date.
Last acquisition by Eli Lilly was XXXXXXXX, XXXXX XXXXX XXXXXX . Eli Lilly acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Eli Lilly founded? | Eli Lilly was founded in 1901. |
| Where is Eli Lilly headquartered? | Eli Lilly is headquartered in United States of America. |
| How many employees does Eli Lilly have? | As of today, Eli Lilly has 47K+ employees. |
| Who is the CEO of Eli Lilly? | Eli Lilly's CEO is Mr. David A. Ricks. |
| Is Eli Lilly publicy listed? | Yes, Eli Lilly is a public company listed on NYS. |
| What is the stock symbol of Eli Lilly? | Eli Lilly trades under LLY ticker. |
| When did Eli Lilly go public? | Eli Lilly went public in 1970. |
| Who are competitors of Eli Lilly? | Similar companies to Eli Lilly include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Eli Lilly? | Eli Lilly's current market cap is $785B |
| What is the current revenue of Eli Lilly? | Eli Lilly's last 12-month revenue is $47.1B. |
| What is the current EBITDA of Eli Lilly? | Eli Lilly's last 12-month EBITDA is $17.3B. |
| What is the current EV/Revenue multiple of Eli Lilly? | Current revenue multiple of Eli Lilly is 17.3x. |
| What is the current EV/EBITDA multiple of Eli Lilly? | Current EBITDA multiple of Eli Lilly is 47.2x. |
| What is the current revenue growth of Eli Lilly? | Eli Lilly revenue growth between 2023 and 2024 was 32%. |
| Is Eli Lilly profitable? | Yes, Eli Lilly is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
